Psychometric validation of the BDI-II among HIV-positive CHARTER study participants

Andréa L. Hobkirk, Amy J. Starosta, Joseph A. De Leo, Christina M. Marra, Robert K. Heaton, Mitch Earleywine, CHARTER Group The CHARTER Group

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Rates of depression are high among individuals living with HIV. Accurate assessment of depressive symptoms among this population is important for ensuring proper diagnosis and treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing depression, however its psychometric properties have not yet been investigated for use with HIV-positive populations in the United States. The current study was the first to assess the psychometric properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple sites across the United States as part of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. The BDI-II test scores showed good internal consistency (α = .93) and adequate test-retest reliability (internal consistency coefficient = 0.83) over a 6-mo period. Using a "gold standard" of major depressive disorder determined by the Composite International Diagnostic Interview, sensitivity and specificity were maximized at a total cut-off score of 17 and a receiver operating characteristic analysis confirmed that the BDI-II is an adequate diagnostic measure for the sample (area under the curve = 0.83). The sensitivity and specificity of each score are provided graphically. Confirmatory factor analyses confirmed the best fit for a three-factor model over one-factor and two-factor models and models with a higher-order factor included. The results suggest that the BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the measure can be differentiated into cognitive, affective, and somatic depressive symptoms.

Original languageEnglish (US)
Pages (from-to)457-466
Number of pages10
JournalPsychological Assessment
Volume27
Issue number2
DOIs
StatePublished - Jun 1 2015

Fingerprint

Psychometrics
HIV
Depression
Equipment and Supplies
Research
Therapeutics
Sensitivity and Specificity
Major Depressive Disorder
Reproducibility of Results
ROC Curve
Population
Statistical Factor Analysis
Area Under Curve
Interviews

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Hobkirk, A. L., Starosta, A. J., De Leo, J. A., Marra, C. M., Heaton, R. K., Earleywine, M., & The CHARTER Group, CHARTER. G. (2015). Psychometric validation of the BDI-II among HIV-positive CHARTER study participants. Psychological Assessment, 27(2), 457-466. https://doi.org/10.1037/pas0000040
Hobkirk, Andréa L. ; Starosta, Amy J. ; De Leo, Joseph A. ; Marra, Christina M. ; Heaton, Robert K. ; Earleywine, Mitch ; The CHARTER Group, CHARTER Group. / Psychometric validation of the BDI-II among HIV-positive CHARTER study participants. In: Psychological Assessment. 2015 ; Vol. 27, No. 2. pp. 457-466.
@article{40c1b9e155cd4eb1bd9bcb7545bf0093,
title = "Psychometric validation of the BDI-II among HIV-positive CHARTER study participants",
abstract = "Rates of depression are high among individuals living with HIV. Accurate assessment of depressive symptoms among this population is important for ensuring proper diagnosis and treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing depression, however its psychometric properties have not yet been investigated for use with HIV-positive populations in the United States. The current study was the first to assess the psychometric properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple sites across the United States as part of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. The BDI-II test scores showed good internal consistency (α = .93) and adequate test-retest reliability (internal consistency coefficient = 0.83) over a 6-mo period. Using a {"}gold standard{"} of major depressive disorder determined by the Composite International Diagnostic Interview, sensitivity and specificity were maximized at a total cut-off score of 17 and a receiver operating characteristic analysis confirmed that the BDI-II is an adequate diagnostic measure for the sample (area under the curve = 0.83). The sensitivity and specificity of each score are provided graphically. Confirmatory factor analyses confirmed the best fit for a three-factor model over one-factor and two-factor models and models with a higher-order factor included. The results suggest that the BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the measure can be differentiated into cognitive, affective, and somatic depressive symptoms.",
author = "Hobkirk, {Andr{\'e}a L.} and Starosta, {Amy J.} and {De Leo}, {Joseph A.} and Marra, {Christina M.} and Heaton, {Robert K.} and Mitch Earleywine and {The CHARTER Group}, {CHARTER Group}",
year = "2015",
month = "6",
day = "1",
doi = "10.1037/pas0000040",
language = "English (US)",
volume = "27",
pages = "457--466",
journal = "Psychological Assessment",
issn = "1040-3590",
publisher = "American Psychological Association Inc.",
number = "2",

}

Hobkirk, AL, Starosta, AJ, De Leo, JA, Marra, CM, Heaton, RK, Earleywine, M & The CHARTER Group, CHARTERG 2015, 'Psychometric validation of the BDI-II among HIV-positive CHARTER study participants', Psychological Assessment, vol. 27, no. 2, pp. 457-466. https://doi.org/10.1037/pas0000040

Psychometric validation of the BDI-II among HIV-positive CHARTER study participants. / Hobkirk, Andréa L.; Starosta, Amy J.; De Leo, Joseph A.; Marra, Christina M.; Heaton, Robert K.; Earleywine, Mitch; The CHARTER Group, CHARTER Group.

In: Psychological Assessment, Vol. 27, No. 2, 01.06.2015, p. 457-466.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Psychometric validation of the BDI-II among HIV-positive CHARTER study participants

AU - Hobkirk, Andréa L.

AU - Starosta, Amy J.

AU - De Leo, Joseph A.

AU - Marra, Christina M.

AU - Heaton, Robert K.

AU - Earleywine, Mitch

AU - The CHARTER Group, CHARTER Group

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Rates of depression are high among individuals living with HIV. Accurate assessment of depressive symptoms among this population is important for ensuring proper diagnosis and treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing depression, however its psychometric properties have not yet been investigated for use with HIV-positive populations in the United States. The current study was the first to assess the psychometric properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple sites across the United States as part of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. The BDI-II test scores showed good internal consistency (α = .93) and adequate test-retest reliability (internal consistency coefficient = 0.83) over a 6-mo period. Using a "gold standard" of major depressive disorder determined by the Composite International Diagnostic Interview, sensitivity and specificity were maximized at a total cut-off score of 17 and a receiver operating characteristic analysis confirmed that the BDI-II is an adequate diagnostic measure for the sample (area under the curve = 0.83). The sensitivity and specificity of each score are provided graphically. Confirmatory factor analyses confirmed the best fit for a three-factor model over one-factor and two-factor models and models with a higher-order factor included. The results suggest that the BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the measure can be differentiated into cognitive, affective, and somatic depressive symptoms.

AB - Rates of depression are high among individuals living with HIV. Accurate assessment of depressive symptoms among this population is important for ensuring proper diagnosis and treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing depression, however its psychometric properties have not yet been investigated for use with HIV-positive populations in the United States. The current study was the first to assess the psychometric properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple sites across the United States as part of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. The BDI-II test scores showed good internal consistency (α = .93) and adequate test-retest reliability (internal consistency coefficient = 0.83) over a 6-mo period. Using a "gold standard" of major depressive disorder determined by the Composite International Diagnostic Interview, sensitivity and specificity were maximized at a total cut-off score of 17 and a receiver operating characteristic analysis confirmed that the BDI-II is an adequate diagnostic measure for the sample (area under the curve = 0.83). The sensitivity and specificity of each score are provided graphically. Confirmatory factor analyses confirmed the best fit for a three-factor model over one-factor and two-factor models and models with a higher-order factor included. The results suggest that the BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the measure can be differentiated into cognitive, affective, and somatic depressive symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84930734695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930734695&partnerID=8YFLogxK

U2 - 10.1037/pas0000040

DO - 10.1037/pas0000040

M3 - Article

C2 - 25419643

AN - SCOPUS:84930734695

VL - 27

SP - 457

EP - 466

JO - Psychological Assessment

JF - Psychological Assessment

SN - 1040-3590

IS - 2

ER -